TII
8.3.2021 14:09:09 CET | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced the appointment of international experts in the field of systems security to the Board of Advisors of its Secure Systems Research Centre (SSRC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005482/en/
Secure Systems Research Centre is one of the initial seven dedicated centres at TII and is among the few global centres of its kind to bring together experts to conduct groundbreaking research in the field of secure systems. The distinguished new Board have combined expertise in security and resilience relating to autonomous computing and will guide the efforts of the Centre’s research team in developing end-to-end solutions to protect cyber-physical and autonomous systems.
The Board of Advisors comprises:
Prof. Ernesto Damiani, Professor, Department of Electrical Engineering and Computer Science, Senior Director, Artificial Intelligence & Intelligent Systems Institute, Director of the Center for Cyber Physical Systems (C2PS), Khalifa University in the UAE, whose research interests include secure service-oriented architectures, privacy-preserving big data analytics and cyber-physical systems security.
Dr Hoda Alkhzaimi, Research Assistant Professor at New York University Abu Dhabi (NYUAD) and Director of the University’s Center of Cyber Security, who was associated with research and development posts in cybersecurity and cryptology. Her research interests include unmanned aerial vehicle (UAV) security, cryptology, cryptanalysis, and building security hardware and software components.
Dr Bushra Alblooshi, Head of Research and Innovation at Dubai Electronic Security Center (DESC), who is focused on researching cloud computing, cybersecurity, computer forensics and cryptography.
Prof. Inseok Hwang, Professor at the School of Aeronautics and Astronautics at Purdue University, who specialises in research on intelligent and high assurance autonomy for cyber-physical systems with applications to complex networked systems, such as multi-vehicle systems.
Prof. Dongyan Xu, Samuel D. Conte Professor of Computer Science at Purdue University, specialises in research focused on cyber and cyber-physical security.
Prof. Taesoo Kim is Associate Professor at the School of Computer Science at the Georgia Institute of Technology, and his research interests span systems security architecture and design, threat intelligence, internet infrastructure and operating systems, machine learning, and programming languages.
Prof. Wenke Lee is Professor of Computer Science and John P. Imlay Jr. Chair, College of Computing at the Georgia Institute of Technology, and is one of the most prolific and influential cybersecurity researchers in the world. His research specialty is systems and network security, applied cryptography and machine learning.
Dr Harry Edelman is CEO of architectural consultancy Edelman Group and co-founder of AIDOMUS, a machine learning and IoT-based startup initiative for smart urban services. His work has focused on various aspects of integrated urban developments, including smart urban energy design and mobility.
Dr Shreekant (Ticky) Thakkar, Chief Researcher at Secure Systems Research Centre, said: “The Centre combines fundamental and applied research to set new standards and act as a catalyst to transform problems into solutions. The goal of the research team is to create new technologies for the development of end-to-end security and resilience in cyber-physical and autonomous systems.”
Research in security and resilience in cyber-physical and autonomous systems will ultimately lead to groundbreaking efforts in ensuring the safety and economic prosperity of our communities. The Board of Advisors will guide the expert SSRC researchers in carrying out such cutting-edge research while also creating new opportunities to train aspiring young UAE nationals in these significant fields.
For more information about Secure Systems Research Centre (SSRC), visit tii.ae/securesystems
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005482/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
